Premium Nahrungsergänzungsmittel | artgerecht

SLC6A8 - Creatine Transporter Gene and Deficiency

SLC6A8 is a gene encoding the creatine transporter CT1. Mutations cause a rare X-linked metabolic disorder characterised by intellectual disability and developmental delay.

Regular tips about health Regular tips about health

Things worth knowing about "SLC6A8"

SLC6A8 is a gene encoding the creatine transporter CT1. Mutations cause a rare X-linked metabolic disorder characterised by intellectual disability and developmental delay.

What is SLC6A8?

SLC6A8 (Solute Carrier Family 6 Member 8) is a gene located on the X chromosome that encodes the creatine transporter CT1. This transporter protein is responsible for the cellular uptake of creatine, particularly in neurons and muscle cells. Creatine plays a central role in cellular energy metabolism by serving as an energy buffer in the form of phosphocreatine. Mutations in the SLC6A8 gene cause the creatine transporter deficiency syndrome (also known as X-linked creatine transporter deficiency), a rare inherited metabolic disorder.

Function of the SLC6A8 Protein

The transporter protein encoded by SLC6A8 belongs to the family of sodium- and chloride-dependent neurotransmitter transporters. It actively transports creatine across cell membranes, including the blood-brain barrier and cell membranes in the brain and skeletal muscle. Without a functional CT1 transporter, creatine cannot be adequately taken up into brain cells, leading to cerebral creatine deficiency.

Causes and Genetics

The SLC6A8 gene is located on the X chromosome (Xq28). Since the condition is inherited in an X-linked recessive manner, male patients are predominantly and more severely affected, while female carriers often exhibit milder symptoms or remain asymptomatic. Known mutation types include:

Missense mutations (point mutations within the coding region)
Nonsense mutations (premature stop codon)
Frameshift mutations (insertions or deletions)
Large deletions of the SLC6A8 gene

Symptoms

The clinical features of SLC6A8 deficiency include:

Intellectual disability (ranging from mild to severe)
Speech and language impairment, often with significant delay in speech development
Behavioural problems, including features resembling autism spectrum disorder
Epilepsy (various types of seizures)
Muscular hypotonia (reduced muscle tone) and delayed motor development
Hyperactivity and attention deficits in some patients

Female carriers may show mild cognitive impairment or behavioural difficulties.

Diagnosis

Diagnosis is established through several steps:

Urinary creatine-to-creatinine ratio: An elevated ratio in urine serves as an initial biochemical indicator.
Magnetic resonance spectroscopy (MRS) of the brain: Reveals a markedly reduced or absent creatine peak in the brain.
Molecular genetic testing: Identification of a pathogenic variant in the SLC6A8 gene through sequencing.
Functional transporter assay: Measurement of creatine uptake in fibroblasts or erythrocytes as additional confirmation.

Treatment

There is currently no curative treatment. Management is symptomatic and aims to improve creatine availability in the brain:

High-dose creatine supplementation: Despite the transporter defect, a small amount of creatine may enter the brain via passive diffusion; however, clinical benefit is limited and varies between individuals.
Glycine and arginine supplementation: These precursors of creatine biosynthesis are being explored to support endogenous creatine production.
Antiepileptic therapy: To manage seizures.
Early intervention and therapies: Speech therapy, physiotherapy, occupational therapy, and educational support to promote development.

Novel therapeutic approaches such as gene therapy and the development of creatine prodrugs designed to bypass the defective transporter are currently under investigation.

References

Stockler S, Schutz PW, Salomons GS. Cerebral creatine deficiency syndromes: clinical aspects, treatment and pathophysiology. Subcellular Biochemistry, 2007;46:149-166.
Arias A, Corbella M, Fons C, et al. Creatine transporter deficiency: prevalence among males with intellectual disability and functional characterization of the mutation. Clinical Biochemistry, 2007;40(16-17):1223-1228.
National Center for Biotechnology Information (NCBI). Gene: SLC6A8. Available at: https://www.ncbi.nlm.nih.gov/gene/6535

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.